| Proximal dysfunction features . | Overall, n = 23 . | Overall, n . | Ifosfamide . | Overall, n . | Ifosfamide + cisplatin . | P-value . |
|---|---|---|---|---|---|---|
| Hypokalaemia, n (%) | 20 (87.0) | 14 | 11 (78.6) | 9 | 9 (100) | NS |
| Metabolic acidosis, n (%) | 12 (52.2) | 12 | 6 (50) | 8 | 6 (75) | NS |
| Hypophosphataemia, n (%) | 14 (61.0) | 14 | 8 (57.1) | 8 | 6 (75) | NS |
| TmPO4²−/eGFR < 0.80, n (%) | 9 (39.1) | 6 | 6 (100) | 3 | 3 (100) | NS |
| Hypouricaemia, n (%) | 9 (39.1) | 11 | 5 (45.4) | 5 | 4 (80) | NS |
| UAFE > 10%, n (%) | 5 (21.7) | 3 | 3 (100) | 2 | 2 (100) | NS |
| Low weight proteinuria, n (%) | 10 (43.5) | 10 | 7 (70) | 6 | 3 (50) | NS |
| Proximal dysfunction features . | Overall, n = 23 . | Overall, n . | Ifosfamide . | Overall, n . | Ifosfamide + cisplatin . | P-value . |
|---|---|---|---|---|---|---|
| Hypokalaemia, n (%) | 20 (87.0) | 14 | 11 (78.6) | 9 | 9 (100) | NS |
| Metabolic acidosis, n (%) | 12 (52.2) | 12 | 6 (50) | 8 | 6 (75) | NS |
| Hypophosphataemia, n (%) | 14 (61.0) | 14 | 8 (57.1) | 8 | 6 (75) | NS |
| TmPO4²−/eGFR < 0.80, n (%) | 9 (39.1) | 6 | 6 (100) | 3 | 3 (100) | NS |
| Hypouricaemia, n (%) | 9 (39.1) | 11 | 5 (45.4) | 5 | 4 (80) | NS |
| UAFE > 10%, n (%) | 5 (21.7) | 3 | 3 (100) | 2 | 2 (100) | NS |
| Low weight proteinuria, n (%) | 10 (43.5) | 10 | 7 (70) | 6 | 3 (50) | NS |
NS, not significant.
| Proximal dysfunction features . | Overall, n = 23 . | Overall, n . | Ifosfamide . | Overall, n . | Ifosfamide + cisplatin . | P-value . |
|---|---|---|---|---|---|---|
| Hypokalaemia, n (%) | 20 (87.0) | 14 | 11 (78.6) | 9 | 9 (100) | NS |
| Metabolic acidosis, n (%) | 12 (52.2) | 12 | 6 (50) | 8 | 6 (75) | NS |
| Hypophosphataemia, n (%) | 14 (61.0) | 14 | 8 (57.1) | 8 | 6 (75) | NS |
| TmPO4²−/eGFR < 0.80, n (%) | 9 (39.1) | 6 | 6 (100) | 3 | 3 (100) | NS |
| Hypouricaemia, n (%) | 9 (39.1) | 11 | 5 (45.4) | 5 | 4 (80) | NS |
| UAFE > 10%, n (%) | 5 (21.7) | 3 | 3 (100) | 2 | 2 (100) | NS |
| Low weight proteinuria, n (%) | 10 (43.5) | 10 | 7 (70) | 6 | 3 (50) | NS |
| Proximal dysfunction features . | Overall, n = 23 . | Overall, n . | Ifosfamide . | Overall, n . | Ifosfamide + cisplatin . | P-value . |
|---|---|---|---|---|---|---|
| Hypokalaemia, n (%) | 20 (87.0) | 14 | 11 (78.6) | 9 | 9 (100) | NS |
| Metabolic acidosis, n (%) | 12 (52.2) | 12 | 6 (50) | 8 | 6 (75) | NS |
| Hypophosphataemia, n (%) | 14 (61.0) | 14 | 8 (57.1) | 8 | 6 (75) | NS |
| TmPO4²−/eGFR < 0.80, n (%) | 9 (39.1) | 6 | 6 (100) | 3 | 3 (100) | NS |
| Hypouricaemia, n (%) | 9 (39.1) | 11 | 5 (45.4) | 5 | 4 (80) | NS |
| UAFE > 10%, n (%) | 5 (21.7) | 3 | 3 (100) | 2 | 2 (100) | NS |
| Low weight proteinuria, n (%) | 10 (43.5) | 10 | 7 (70) | 6 | 3 (50) | NS |
NS, not significant.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
